Cadila Health gets US nod for bromocriptine mesylate
MUMBAI, Aug 1 (Reuters) - Drug maker Cadila Healthcare Ltd (CADI.BO: Quote, Profile, Research) said on Friday it received the U.S. Food and Drug Administration approval for its generic bromocriptine mesylate capsules.
The drug, used to treat problems with menstrual period and infertility in women, had sales of $11.4 million in 2007, the company said in a statement. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Dubai Debt Fears
Banks outside the Gulf played down their exposure to Dubai debt, after fears the emirate could default and even derail world economic recovery prompted a sell-off in global markets. Full Article | Slideshow
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage






India
US
UK







